Key facts
- This page summarizes Javier Rodriguez's Form 4 filing for BioXcel Therapeutics, Inc. (BTAI).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 01 Apr 2025, 18:04.
Javier Rodriguez - 22 Jul 2024 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)
- Reporting relationship
- Chief Legal Officer, Senior Vice President and Corporate Secretary
- Issuer ticker
- BTAI
- Reported as of
- 22 Jul 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 01 Apr 2025, 18:04:24 UTC
- Prior SEC filing
- 18 Jun 2024
- Next SEC filing
- 17 Sep 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Richard Steinhart, Attorney-in-Fact for Javier Rodriguez
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Javier Rodriguez filed Form 4 for BioXcel Therapeutics, Inc. (BTAI) on 01 Apr 2025.
Change
- Previous filing in this sequence was filed on 18 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BTAI
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +625
- Change %
- Price
- $0.000000
- Shares after
- 625
- Date
- 22 Jul 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 625
- Exercise price
- Footnotes
- F1, F2, F3
BTAI
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +1,875
- Change %
- Price
- $0.000000
- Shares after
- 1,875
- Date
- 22 Jul 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,875
- Exercise price
- $1.20
- Footnotes
- F2, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
Footnote F2
The share amount has been adjusted to reflect the reverse stock split effective on February 7, 2025 whereby every sixteen shares issued and outstanding prior to the split were combined and converted into one share of common stock.
Footnote F3
The RSUs will vest and settle as to 100% of the total number of RSUs on the first anniversary of the grant date, subject to the Reporting Person's continuous employment with the Issuer through such date.
Footnote F4
The Reporting Person was granted an option to purchase 1,875 shares of common stock, which vests as to 50% on each of the first and second anniversaries of the grant date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
SEC remarks
Chief Legal Officer, Senior Vice President and Corporate Secretary